Cellectis
Tracked across 3 events · 19 articles · First seen Apr 10, 2026 · Last active Jul 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Cellectis received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States — Food and Drug Administration>>> for its product candidate, lasme-cel, which is a significant positive development for the company's clinical program and market position.
Jun 09, 2026 · 6 articles
Tech
Impact: Cellectis presented positive Phase 1 data for its CAR-T therapies, lasme-cel and eti-cel, which could lead to accelerated development and increased investor confidence.
Jun 11, 2026 · 7 articles
Business
Impact: Cellectis is the company providing monthly updates on its total number of shares and voting rights.
Jun 03, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Cellectis live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard